On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened higher 1.65% from the last session, before settling in for the closing price of $6.68. Price fluctuations for RXRX have ranged from $5.60 to $12.36 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 112.62%. Company’s average yearly earnings per share was noted 2.54% at the time writing. With a float of $305.72 million, this company’s outstanding shares have now reached $389.55 million.
In terms of profitability, gross margin is 10.66%, operating margin of -814.58%, and the pretax margin is -790.4%.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Recursion Pharmaceuticals Inc is 23.95%, while institutional ownership is 60.16%. The most recent insider transaction that took place on Mar 05 ’25, was worth 131,600. In this transaction Chief Executive Officer of this company sold 20,000 shares at a rate of $6.58, taking the stock ownership to the 1,256,024 shares. Before that another transaction happened on Mar 06 ’25, when Company’s Chief Executive Officer sold 20,000 for $6.37, making the entire transaction worth $127,400. This insider now owns 1,256,024 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.54% per share during the next fiscal year.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Check out the current performance indicators for Recursion Pharmaceuticals Inc (RXRX). In the past quarter, the stock posted a quick ratio of 3.81. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 46.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.66, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -1.43 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
The latest stats from [Recursion Pharmaceuticals Inc, RXRX] show that its last 5-days average volume of 16.04 million was inferior to 24.03 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 77.64%. Additionally, its Average True Range was 0.65.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 17.60%, which indicates a significant decrease from 87.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 73.38% in the past 14 days, which was lower than the 99.55% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.40, while its 200-day Moving Average is $7.24. Now, the first resistance to watch is $6.93. This is followed by the second major resistance level at $7.08. The third major resistance level sits at $7.21. If the price goes on to break the first support level at $6.65, it is likely to go to the next support level at $6.52. Assuming the price breaks the second support level, the third support level stands at $6.37.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are currently 401,991K shares outstanding in the company with a market cap of 2.73 billion. Presently, the company’s annual sales total 58,840 K according to its annual income of -463,660 K. Last quarter, the company’s sales amounted to 4,550 K and its income totaled -178,910 K.
